Special Issue

Alternative Approaches to Treating Antimicrobial Resistant Infections - 2nd Volume

Message from the Guest Editors

This Special Issue will focus on alternative approaches to treating antimicrobial-resistant infections. The discovery of antibiotics revolutionized the clinical treatment of bacterial infections. However, this fundamental pillar of modern medicine is now crumbling. The development of novel antimicrobials has slowed down in recent years, and major pharmaceutical firms have withdrawn from the anti-infective research area due to its low profitability. Antimicrobial resistance is now considered one of the greatest risks to humanity. Common surgical procedures and treatments that could lead to immunosuppression may soon be considered high-risk due to the antibiotic crisis. Topics include the development of novel combinatorial therapies based on the repurposing of anti-infectives, host-targeted therapies, bacteriophages, the use of predatory bacteria, bacteriocins, antimicrobial peptides, nanoparticles, natural compounds, immunotherapeutics, probiotics used for competitive exclusion of pathogens, and the development of novel antibacterial compounds.

Guest Editors

Dr. Michal Letek

Department of Molecular Biology, Area of Microbiology, Universidad de León, 24071 Leon, Spain

Dr. Volker Behrends

Department of Life Sciences, University of Roehampton, London, UK

Deadline for manuscript submissions

closed (1 April 2023)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/111579

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

